Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenibut is a neuropsychotropic drug developed in Russia in the 1960s and used primarily as an anxiolytic and nootropic agent. It is structurally similar to gamma-aminobutyric acid (GABA) and acts mainly as a GABA-B receptor agonist with some activity at the GABA-A receptor. Phenibut also stimulates dopamine receptors and antagonizes beta-phenethylamine (PEA), which may contribute to its anxiolytic effects. It is widely used in Russia and some Eastern European countries for treating anxiety, insomnia, tension, fear, alcohol withdrawal syndrome, stammering (stuttering), vestibular disorders, depression-related asthenia (weakness), post-traumatic stress disorder (PTSD), and as a pre/post-operative medication. Phenibut has not been approved by regulatory agencies such as the FDA in the United States or EMA in Europe due to safety concerns including dependence potential[1][2][3][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenibut.